TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Moleculin Biotech ( (MBRX) ) has shared an announcement.
On November 12, 2025, Moleculin Biotech announced a research and material transfer agreement with the University of North Carolina at Chapel Hill to evaluate Annamycin for pancreatic cancer treatment. This collaboration aims to enhance the delivery of Annamycin in preclinical studies, potentially expanding its clinical applications and strengthening Moleculin’s oncology development pipeline.
The most recent analyst rating on (MBRX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. Their lead program, Annamycin, is an advanced anthracycline designed to overcome multidrug resistance and avoid cardiotoxicity, with ongoing development for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases.
Average Trading Volume: 4,012,080
Technical Sentiment Signal: Sell
Current Market Cap: $23.91M
See more data about MBRX stock on TipRanks’ Stock Analysis page.